Otsuka subsidiary gets date with FDA for Lonsurf combo; Vaxcyte sells stock to bankroll PhIII vaccine trial
Otsuka subsidiary Taiho Oncology announced Tuesday morning that the FDA has accepted its application for a combo indication for Lonsurf, which is currently approved for third- or fourth-line metastatic colorectal cancer.
With priority review, the FDA has until Aug. 13 to decide on whether or not to approve Taiho’s drug in combination with Roche’s Avastin in the same lines of treatment that Lonsurf is already available as a monotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.